This follow-up trial builds on AtriAN’s initial safety and feasibility study and aims to assess the efficacy of its cardioneuroablation treatment in patients with atrial fibrillation.  GALWAY, Ireland, Sept. 6, 2022 /PRNewswire/ — AtriAN Medical today announced that it has completed enrollment of a second study using its selective pulsed field ablation (PFA) […]